1196 related articles for article (PubMed ID: 27816492)
21. Safety, Efficacy, and Pharmacodynamics of Tremelimumab Plus Durvalumab for Patients With Unresectable Hepatocellular Carcinoma: Randomized Expansion of a Phase I/II Study.
Kelley RK; Sangro B; Harris W; Ikeda M; Okusaka T; Kang YK; Qin S; Tai DW; Lim HY; Yau T; Yong WP; Cheng AL; Gasbarrini A; Damian S; Bruix J; Borad M; Bendell J; Kim TY; Standifer N; He P; Makowsky M; Negro A; Kudo M; Abou-Alfa GK
J Clin Oncol; 2021 Sep; 39(27):2991-3001. PubMed ID: 34292792
[TBL] [Abstract][Full Text] [Related]
22. Long term survival with cytotoxic T lymphocyte-associated antigen 4 blockade using tremelimumab.
Eroglu Z; Kim DW; Wang X; Camacho LH; Chmielowski B; Seja E; Villanueva A; Ruchalski K; Glaspy JA; Kim KB; Hwu WJ; Ribas A
Eur J Cancer; 2015 Nov; 51(17):2689-97. PubMed ID: 26364516
[TBL] [Abstract][Full Text] [Related]
23. Immune checkpoint inhibitors for hepatocellular carcinoma.
El Dika I; Khalil DN; Abou-Alfa GK
Cancer; 2019 Oct; 125(19):3312-3319. PubMed ID: 31290997
[TBL] [Abstract][Full Text] [Related]
24. A phase 2 study of tremelimumab in patients with advanced uveal melanoma.
Joshua AM; Monzon JG; Mihalcioiu C; Hogg D; Smylie M; Cheng T
Melanoma Res; 2015 Aug; 25(4):342-7. PubMed ID: 26050146
[TBL] [Abstract][Full Text] [Related]
25. Combination of radiofrequency ablation and sequential cellular immunotherapy improves progression-free survival for patients with hepatocellular carcinoma.
Cui J; Wang N; Zhao H; Jin H; Wang G; Niu C; Terunuma H; He H; Li W
Int J Cancer; 2014 Jan; 134(2):342-51. PubMed ID: 23825037
[TBL] [Abstract][Full Text] [Related]
26. Phase I/II trial of tremelimumab in patients with metastatic melanoma.
Camacho LH; Antonia S; Sosman J; Kirkwood JM; Gajewski TF; Redman B; Pavlov D; Bulanhagui C; Bozon VA; Gomez-Navarro J; Ribas A
J Clin Oncol; 2009 Mar; 27(7):1075-81. PubMed ID: 19139427
[TBL] [Abstract][Full Text] [Related]
27. Effectiveness of combined (131)I-chTNT and radiofrequency ablation therapy in treating advanced hepatocellular carcinoma.
Tu J; Ji J; Wu F; Wang Y; Zhang D; Zhao Z; Ying X
Cell Biochem Biophys; 2015 Mar; 71(2):777-84. PubMed ID: 25293788
[TBL] [Abstract][Full Text] [Related]
28. Ctla-4 blockade confers lymphocyte resistance to regulatory T-cells in advanced melanoma: surrogate marker of efficacy of tremelimumab?
Ménard C; Ghiringhelli F; Roux S; Chaput N; Mateus C; Grohmann U; Caillat-Zucman S; Zitvogel L; Robert C
Clin Cancer Res; 2008 Aug; 14(16):5242-9. PubMed ID: 18698043
[TBL] [Abstract][Full Text] [Related]
29. Clinical development of the anti-CTLA-4 antibody tremelimumab.
Ribas A
Semin Oncol; 2010 Oct; 37(5):450-4. PubMed ID: 21074059
[TBL] [Abstract][Full Text] [Related]
30. Hepatic intra-arterial interferon alpha 2b-based immunotherapy combined with 5-fluorouracil (5-FU)-based systemic chemotherapy for patients with hepatocellular carcinoma (HCC) not responsive and/or not eligible for conventional treatments: a pilot study.
Vitale FV; Romeo P; Vasta F; Panebianco V; Calì S; Rotondo S; Ferraù F; La Greca M
Anticancer Res; 2007; 27(6B):4077-81. PubMed ID: 18225574
[TBL] [Abstract][Full Text] [Related]
31. Recent developments with immunotherapy for hepatocellular carcinoma.
Waidmann O
Expert Opin Biol Ther; 2018 Aug; 18(8):905-910. PubMed ID: 29995439
[TBL] [Abstract][Full Text] [Related]
32. Phase I/II study of PexaVec in combination with immune checkpoint inhibition in refractory metastatic colorectal cancer.
Monge C; Xie C; Myojin Y; Coffman K; Hrones DM; Wang S; Hernandez JM; Wood BJ; Levy EB; Juburi I; Hewitt SM; Kleiner DE; Steinberg SM; Figg WD; Redd B; Homan P; Cam M; Ruf B; Duffy AG; Greten TF
J Immunother Cancer; 2023 Feb; 11(2):. PubMed ID: 36754451
[TBL] [Abstract][Full Text] [Related]
33. Liver immunotolerance and hepatocellular carcinoma: Patho-physiological mechanisms and therapeutic perspectives.
Roth GS; Decaens T
Eur J Cancer; 2017 Dec; 87():101-112. PubMed ID: 29145036
[TBL] [Abstract][Full Text] [Related]
34. An autologous in situ tumor vaccination approach for hepatocellular carcinoma. 2. Tumor-specific immunity and cure after radio-inducible suicide gene therapy and systemic CD40-ligand and Flt3-ligand gene therapy in an orthotopic tumor model.
Kawashita Y; Deb NJ; Garg MK; Kabarriti R; Fan Z; Alfieri AA; Roy-Chowdhury J; Guha C
Radiat Res; 2014 Aug; 182(2):201-10. PubMed ID: 24992166
[TBL] [Abstract][Full Text] [Related]
35. Immune checkpoint therapy in liver cancer.
Xu F; Jin T; Zhu Y; Dai C
J Exp Clin Cancer Res; 2018 May; 37(1):110. PubMed ID: 29843754
[TBL] [Abstract][Full Text] [Related]
36. Vascular endothelial growth factor monitoring in advanced hepatocellular carcinoma patients treated with radiofrequency ablation plus octreotide: a single center experience.
Montella L; Addeo R; Caraglia M; Faiola V; Guarrasi R; Vincenzi B; Palmeri A; Capasso E; Nocera V; Tarantino L; Ariete M; Martorelli A; Del Prete S
Oncol Rep; 2008 Aug; 20(2):385-90. PubMed ID: 18636202
[TBL] [Abstract][Full Text] [Related]
37. Comparative analysis of various tumor-associated antigen-specific t-cell responses in patients with hepatocellular carcinoma.
Mizukoshi E; Nakamoto Y; Arai K; Yamashita T; Sakai A; Sakai Y; Kagaya T; Yamashita T; Honda M; Kaneko S
Hepatology; 2011 Apr; 53(4):1206-16. PubMed ID: 21480325
[TBL] [Abstract][Full Text] [Related]
38. Combined immunostimulatory monoclonal antibodies extend survival in an aggressive transgenic hepatocellular carcinoma mouse model.
Morales-Kastresana A; Sanmamed MF; Rodriguez I; Palazon A; Martinez-Forero I; Labiano S; Hervas-Stubbs S; Sangro B; Ochoa C; Rouzaut A; Azpilikueta A; Bolaños E; Jure-Kunkel M; Gütgemann I; Melero I
Clin Cancer Res; 2013 Nov; 19(22):6151-62. PubMed ID: 24030703
[TBL] [Abstract][Full Text] [Related]
39. Can Combined Therapy Benefit Immune Checkpoint Blockade Response in Hepatocellular Carcinoma?
Zhongqi F; Xiaodong S; Yuguo C; Guoyue L
Anticancer Agents Med Chem; 2019; 19(2):222-228. PubMed ID: 30426903
[TBL] [Abstract][Full Text] [Related]
40. Efficacy, Safety, and Potential Biomarkers of Sunitinib and Transarterial Chemoembolization (TACE) Combination in Advanced Hepatocellular Carcinoma (HCC): Phase II Trial.
Pokuri VK; Tomaszewski GM; Ait-Oudhia S; Groman A; Khushalani NI; Lugade AA; Thanavala Y; Ashton EA; Grande C; Fetterly GJ; Iyer R
Am J Clin Oncol; 2018 Apr; 41(4):332-338. PubMed ID: 27014931
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
